<b>Aims:</b> This study aims to investigate further the function and mechanism of interaction of PEG-SMR-CLU and SMR-CPP peptides with the chaperone protein mortalin and to explore the effect of SMR-derived peptides and mortalin expression on extracellular vesicle release and complement dependent cell toxicity in human breast cancer and leukemia cell lines.
<b>Areas covered</b>: A literature review based on the MEDLINE/PubMed search about biosimilars allied with the FDA and EMA's latest statements of this topic were conducted to summarize the development and the use of currently available biosimilars for BC, with a focus on trastuzumab.
<b>Areas covered</b>: A literature review based on the MEDLINE/PubMed search about biosimilars allied with the FDA and EMA's latest statements of this topic were conducted to summarize the development and the use of currently available biosimilars for BC, with a focus on trastuzumab.
<b>Areas covered</b>: Several studies have investigated the role of adding OFS to tamoxifen and aromatase inhibitors as adjuvant treatment in early breast cancer.
<b>Background:</b> Wnt5a is a nontransforming Wnt family member and identified as an oncogenic role on cell motility of breast cancer and glioblastoma.
<b>Background:</b> Double blockade with pertuzumab and trastuzumab combined with chemotherapy is the standard neoadjuvant treatment for HER2-positive early breast cancer.
<b>Background:</b> Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying a deleterious germline <i>BRCA</i> mutation on ovarian reserve measured by anti-müllerian hormone (AMH) levels of young breast cancer patients receiving (neo)adjuvant cyclophosphamide- and anthracycline-based chemotherapy.
<b>Background:</b> Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) induces aromatase expression in adipose tissue, leading to increased estrogen production that may promote the development and progression of breast cancer.
<b>Background:</b> Smoking is a possible risk factor for breast cancer and has been linked to increased risk of estrogen receptor-positive (ER<sup>+</sup>) disease in some epidemiologic studies.
<b>Background:</b> Transient Receptor Potential Vanilloid 6 (TRPV6), a non-voltage gated calcium channel, is implicated in malignancies and correlates with Gleason scores in prostate cancer and with poor prognosis in breast cancer.
<b>Background:</b> Triple-negative breast cancer (TNBC) is a breast cancer that tests negative forestrogen receptor (ER), progesterone receptors, and human epidermal growth factor receptors 2 (HER2).
<b>Background:</b> Triple-negative breast cancer (TNBC) is a breast cancer that tests negative for estrogen receptor (ER), progesterone receptors, and human epidermal growth factor receptors 2 (HER2).
<b>Background:</b> Using a secondary data analysis from randomized controlled trials comparing one year of resistance exercise (<i>n</i> = 109) to a placebo control condition (<i>n</i> = 106) in postmenopausal, posttreatment breast cancer survivors, we investigated the influence of resistance training and changes in body composition on markers associated with cancer progression.<b>Methods:</b> Measures included serum levels of insulin, IGF-1, IGFBP1-3, leptin, serum amyloid A (SAA), adiponectin, C-reactive protein (CRP), IL1β, TNFα, IL6, and IL8, and body composition (total, lean and fat mass in kg) by DXA at baseline, 6, and 12 months.
<b>Conclusion</b>: Overexpression of TOP2A, MAD2L1, FEN1, EPRS, EXO1, MCM4, PTTG1, RRM2, PSMD14, CDKN3, H2AFZ, CCNE2 and downregulation of FGF2, BCL2, PIK3R1 might serve as diagnosis and poor prognosis biomarkers in breast cancer by more research validation.
<b>Conclusion</b>: This study demonstrated that the low LPP1 expression in breast cancer cells is associated with high levels of cyclin D1/D3 and MMPs as a result of increased transcription by cFOS and cJUN.
<b>Conclusion:</b> Detection of miR 27a expression may serve as a potential sensitive minimally invasive molecular marker for early detection of primary BC.